Skip to main content
Industry News
Dapagliflozin may reduce AFib risks, study says
2/13/2020

Patients who had type 2 diabetes and cardiovascular risk factors who took dapagliflozin had a 19% lower risk of a first atrial fibrillation or atrial flutter event, compared with patients taking a placebo, a study in Circulation showed. Total AFib and atrial flutter events also was lower among patients taking dapagliflozin, compared with those taking a placebo.

Full Story: